The ACR of 2017 is a very different beast. It was on a downward decline from its Axiron gravy train. We are now talking generics, under the new (accelerated) regulatory regime. Chalk & cheese. That said, I'm not expert in the industry. I won't pretend to be. Call me naive, but I'm choosing to believe management are not blatant liars, here. I still see an assymetruic opportunity here - though yes, may patience is wearing thin.
What matters to me, here, is that I am not unique in loss of patience here.
Add to My Watchlist
What is My Watchlist?
